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Abstract
Background—Health insurance plans have historically limited the benefits for mental health and 
substance abuse (MH/SA) services compared to benefits for physical health services. In recent 
years, legislative and policy initiatives in the U.S. have been taken to expand MH/SA health 
insurance benefits and achieve parity with physical health benefits. The relevance of these 
legislations for international audiences is also explored, particularly for the European context.
Aims of the Study—This paper reviews the evidence of costs and economic benefits of 
legislative or policy interventions to expand MH/SA health insurance benefits in the U.S. The 
objectives are to assess the economic value of the interventions by comparing societal cost to 
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societal benefits, and to determine impact on costs to insurance plans resulting from expansion of 
these benefits.
Methods—The search for economic evidence covered literature published from January 1950 to 
March 2011 and included evaluations of federal and state laws or rules that expanded MH/SA 
benefits as well as voluntary actions by large employers. Two economists screened and abstracted 
the economic evidence of MH/SA benefits legislation based on standard economic and actuarial 
concepts and methods.
Results—The economic review included 12 studies: eleven provided evidence on cost impact to 
health plans, and one estimated the effect on suicides. There was insufficient evidence to 
determine if the intervention was cost-effective or cost-saving. However, the evidence indicates 
that MH/SA benefits expansion did not lead to any substantial increase in costs to insurance plans, 
measured as a percentage of insurance premiums.
Discussion and Limitations—This review is unable to determine the overall economic value 
of policies that expand MH/SA insurance benefits due to lack of cost-effectiveness and cost-
benefit studies, predominantly due to the lack of evaluations of morbidity and mortality outcomes. 
This may be remedied in time when long-term MH/SA patient-level data becomes available to 
researchers. A limitation of this review is that legislations considered here have been superseded 
by recent legislations that have stronger and broader impacts on MH/SA benefits within private 
and public insurance: Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) and the 
Patient Protection and Affordable Care Act of 2010 (ACA).
Implications for Future Research—Economic assessments over the long term such as cost 
per QALY saved and cost-benefit will be feasible as more data becomes available from plans that 
implemented recent expansions of MH/SA benefits. Results from these evaluations will allow a 
better estimate of the economic impact of the interventions from a societal perspective. Future 
research should also evaluate the more downstream effects on business decisions about labor, such 
as effects on hiring, retention, and the offer of health benefits as part of an employee 
compensation package. Finally, the economic effect of the far reaching ACA of 2010 on mental 
health and substance abuse prevalence and care is also a subject of future research.
Introduction
Background
Historically, private health insurance plans in the U.S. limited mental health and substance 
abuse (MH/SA) benefits compared to the benefits covered for physical health.1,2 MH/SA 
benefits were usually controlled through lower quantitative limits on specific services and 
higher copayments and deductibles.3 Monitoring and gatekeeping the demand for mental 
health treatment and services was believed to be more difficult than for physical health.4
Various actuarial models from the mid-1990s predicted that federal legislation expanding 
mental health benefits would increase utilization of those services and insurance premium 
would increase anywhere from 3.2% to 11.4%.5 This expectation found empirical basis in 
early results from the Rand Health Insurance Experiment (RAND HIE)6, which 
demonstrated higher utilization associated with lower patient cost-sharing or out-of-pocket 
(OOP) cost.
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Beginning in the 1990s, federal and state legislations, executive orders and corporate policy 
changes sought to relax the quantitative and financial limits on behavioral health benefits in 
group health insurance plans.7,8 Similar expansions in MH/SA benefits in relation to 
physical benefits were implemented and evaluated by large private and public employers 
with self-insured plans. Though more recent federal legislation such as the Mental Health 
Parity and Addiction Equity Act of 2008 (MHPAEA) and the Affordable Care Act of 2010 
(ACA) were enacted, they have not been in effect over a sufficiently long period to produce 
published evaluations.
The market for voluntary health insurance (private health insurance) in Europe is small 
given the prevalence of universal public insurance in all but a few countries in Central and 
Eastern Europe. However, the experience of the U.S. in implementing parity in private 
insurance benefits for mental health is relevant for Europe. Unequal access to health 
promotion, prevention and treatment for mental health exists also in Europe’s systems of 
universal coverage, prompting national legislations such as in the U.K.9 It is noted that the 
higher out- of- pocket costs required for specialist mental health care constitute disparity in 
access to mental health relative to physical health services for several Western European 
countries.10 Further, it is a practice in many European countries to transfer long term care of 
chronic aspects of mental health out of the health care system and into the social care system 
with plausibly different eligibility requirements, means testing, and out- of- pocket cost.11 
The U.S. enacted policies and laws to require equal access for mental health services and 
their consequences for cost and health outcomes are thus relevant for Europe irrespective of 
whether the final payer is private insurance or a public fund. Finally, mental health is 
integral to both capabilities and the exercise of those capabilities for the well-being of all 
individuals12 and it is therefore a matter of justice that the objectives of good mental and 
physical health have equal weight for all national health systems.
Aims of the Study
A recent evidence review,13 conducted for the Community Preventive Services Task Force 
(CPSTF), found that these interventions that expanded mental health benefits were effective 
in improving financial protection and increasing appropriate utilization of mental health 
services for people with mental illness. The CPSTF is an independent, nonfederal, unpaid 
panel of public health and prevention experts, established in 1996 by the U.S. Department of 
Health and Human Services to identify population health interventions that are scientifically 
proven to save lives, increase lifespans, and improve quality of life for the U.S. population. 
The objective of the present study is to review the evidence of economic effects of the 
interventions that expanded mental health benefits. In particular, the research questions and 
the associated economic outcomes of interest are: (1) What is the cost of implementing and 
administering policies that expand MH/SA health insurance benefits? (2) What is the effect 
of MH/SA benefits expansion on healthcare cost? (3) What is the effect of the intervention 
on productivity at the worksite? (4) What is the economic impact of intervention on the plan 
provider?
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Methods
The general methods for conducting systematic economic reviews for the CPSTF can be 
found at http://www.thecommunityguide.org/about/economics.html. The translation of 
general methods to the present review is detailed below. A coordination team (team), 
comprising of subject matter experts on mental health from various organizations as well as 
systematic review experts, developed an analytic framework and guided a systematic search 
to identify relevant studies that reported economic information about the intervention. 
Details about intervention definitions and the analytic framework may be found at http://
www.thecommunityguide.org/mentalhealth/benefitslegis.html.
Identification and Selection of Studies
The search covered the period January 1950 to February 2011 and used the following 
sources: Center for Reviews and Dissemination (CRD) at the University of York, Medline, 
EconLit, PsycINFO, and Google Scholar. Detailed strategy and criteria for the economic 
search can be found at http://www.thecommunityguide.org/mentalhealth/SS-benefitslegis-
econ.html. Studies that contained economic information were also identified from the search 
yield for the effectiveness review.13 Studies were included if they: (1) met the definition of 
intervention; (2) were in English; (3) were conducted in a high income country;14 (4) 
estimated or modeled at least one of the following: intervention cost; effect on healthcare 
cost; effect on productivity at work; effect on cost per life year gained or cost per quality/
disability adjusted life year saved/averted.
Concepts and Measurements
Interventions are those that expand MH/SA benefits through legislations and policies, 
regardless of the mechanism (e.g. federal or state law or executive order, administrative rule, 
employer benefits policy).
Intervention Cost is the dollar value of time and materials used by experts, interest groups, 
leaders/legislators, and staff in their activities both in favor and in opposition to the policies, 
and the resources needed to monitor and enforce the policies, once they are in place.
Cost Consequences for Healthcare due to Intervention measure the change in the sum of 
inpatient and outpatient care costs plus the cost of drugs for MH/SA due to the expansion of 
benefits. It is usually measured from claims data. The out-of-pocket (OOP) cost to the 
covered patient was included in the review of effectiveness13 and is not considered here 
since it is not a cost to the plan.
Healthcare cost can either increase or decrease in response to the benefits expansion. If the 
current users of MH/SA services increase their use, or other enrollees start to use these 
services once they became more readily accessible, the cost might increase. On the other 
hand, if expanded MH/SA benefits improve prevention and treatment and reduce morbidity, 
healthcare cost might decrease.
Economic Benefits due to Intervention are the societal economic benefits arising from health 
care costs averted and productivity gains in worksites due to improvements in health. 
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Improvements in health in turn reduce morbidity and mortality and thereby increase quality-
adjusted life years (QALY) saved or disability-adjusted life years (DALY) averted.
Plan Cost is the cost consequence to the plan provider due to MH/SA benefits expansion and 
is calculated from the change in healthcare cost for MH/SA minus deductibles and other out-
of-pocket costs paid by the patients. Claims data are used to measure changes in healthcare 
utilization from the perspective of the plan provider. Claims are classified as mental health 
or substance abuse treatment based on the diagnosis related group (DRG) code and further 
classified into inpatient and outpatient categories. Claims for drug benefits are often separate 
and managed by specialized vendors.
Assessment of Impact on Plan Provider The economic impact of MH/SA benefits expansion 
from a plan provider’s perspective is assessed by estimating the change in plan cost as a 
percentage of revenues from premiums. This provides a basis to judge whether any observed 
change in cost was small or large in relation to revenue and the plan’s ability to absorb the 
impact of expansion in MH/SA benefits. Operating financials for health insurance plans are 
generally measured in per member per year (PMPY) terms, where member is the plan-
holder who contributes to premiums or for whom the premiums are paid. The plan-holder 
may opt for single coverage, or for family coverage that includes spouse and children. In this 
review, the persons covered under a plan are collectively referred to as enrollees. Research 
and administrative reports generally identified claims with the person for whom expenses 
are incurred while premiums are reported in per member (plan-holder) terms. This review 
constructed per person per year (PPPY) estimates for both the cost and revenue sides of the 
equation, where the person is any enrollee. These standard methods of accounting in 
insurance operations are similar to concepts and methods in a recent background report 
developed by the Congressional Research Services to assist legislators in their debate on 
regulating private health insurance premiums,15 and also in actuarial training materials.16
It is difficult to estimate premium revenues for private group plans because the information 
is generally proprietary and confidential. The review team drew from multiple sources for 
premium, plan type, and enrollment data. The US Office of Personnel Management (OPM) 
provided average premiums (Personal communication with OPM) for various Federal 
Employee Health Benefits (FEHB) plans and the overall counts for plan-holders and 
dependents.17 Premiums for private health insurance plans and the percentage distribution of 
single coverage were obtained from the insurance component of the Medical Expenditure 
Panel Survey (MEPS-IC).18 MEPS-IC is based on data collected by the Agency for 
Healthcare Research and Quality (AHRQ) since 1996 through a survey of private and public 
sector employers. The number of covered dependents on family plans is not available in 
MEPS-IC and national estimate for employer-sponsored plans from the Current Population 
Surveys (CPS) of the U.S. Census Bureau19 was used to estimate this variable.
We chose the premium most appropriate for comparison against the source of claims used in 
the studies to estimate the change in cost of utilization based on: HMO or PPO provider 
type; claims for plan-holders only, plan-holder plus dependents, or dependents only; 
geographic area; federal government, state and local government, or private sector 
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employer; size of private employer; and year claims generated. The following rules were 
followed:
• Claims from HMO – HMO premiums were used
• Claims from PPO – mixed provider premiums were used
• Large employer – used premiums for insurance sponsored by employers with 
greater than 1000 employees
• Years of claims – in pre to post analysis of claims, the premium from the midpoint 
of the pre to post period was used.
• Plan-holder only claims – used premium for single coverage
• Plan-holder plus dependent claims – used weighted single and family premium 
with weights provided by percentage of plan-holders opting for single coverage and 
the average number of dependents in family coverage
• Dependent only claims – used premium for family coverage weighted by average 
number of dependents in family coverage
All monetary values in this review are reported in nominal U.S. dollars and are not adjusted 
for inflation. Adjustments for price level alone are not sufficient to draw valid inferences 
regarding magnitude and direction of change from observations of MH/SA costs that are 
many years apart because recognized MH/SA conditions and available treatments in the two 
periods can be very different. Besides, financial consequence to the insurance plans due to 
expanded benefits is assessed on the basis of the percentage change in claims cost in relation 
to existing health insurance premium for that period, a ratio that does not involve actual 
dollar values.
Listing of Economic Evidence
Findings from the Federal Employees Health Benefits (FEHB) studies are discussed first, 
followed by statewide studies and individual employer studies. The FEHB studies are 
considered strong because of the plans’ large membership and study sample sizes, the 
increased MH/SA benefits that resulted from the executive order, and detailed historical 
claims data that were analyzed for multiple plans. The evidence from statewide mandate 
studies is considered next because the mandated incremental MH/SA benefits applied to a 
large population in a defined geographic area. The evidence from individual private and 
public employers is discussed last because the voluntary nature of their decision to expand 
MH/SA benefits may reflect unobserved selection biases.
Results
A total of 1263 potentially eligible papers were identified from the search, out of which 112 
full text papers were considered after title and abstract screening, to yield 14 papers that met 
all inclusion criteria based on detailed full text review (Figure 1).20–33 Three papers31–33 are 
considered a single study because the same core set of authors analyzed the same plans and 
data, and the conclusions in the last paper drew on results from the previous two. Thus, a 
total of 12 studies (in 14 papers) were included in the review. An additional unpublished 
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report34 was used to adjust estimates in one23 of the included studies. All included studies 
were based in the U.S.
Intervention cost
No studies reported the economic cost of time and materials that brought about the policy 
change expanding MH/SA insurance benefits.
Healthcare cost
All but one26 of the studies reported the effect of benefits expansion on healthcare cost, 
based on estimates from claims for MH/SA treatments. The estimated changes in cost of 
MH/SA utilization are reported below in the section on Cost Impacts for Plan Providers.
Cost-Benefit and Cost-Effectiveness
No studies reported cost per QALY saved or benefit-to-cost ratios for the intervention. The 
absence of this evidence is not unexpected since monetized benefits and QALY would have 
required estimates for morbidity and mortality outcomes due to the intervention, and the 
review of effectiveness also found no evaluations that attempted or were able to measure 
health impact attributable to legislation beyond change in utilization and financial protection 
of the insured.13
Cost Impact on Plan Providers
Federal Employees Health Benefits Program—The Federal Employees Health 
Benefits (FEHB) Program is the largest employer-sponsored health insurance program in the 
U.S. Following executive orders, the Office of Personnel Management (OPM) instituted 
policies requiring that MH/SA benefits be at parity with general medical care with respect to 
features such as deductibles, copayments, and limits on visits and inpatient days. The first 
order was executed in 1967 in the pre–managed-care era and the second in 1999 when 
managed care had become prevalent in the health system.
Four studies of FEHB plans are included, one25 that assessed the effect of the 1967 order 
and three20,21,23 that evaluated effects of the 1999 order (Table 1). In general, the evidence 
from the FEHB studies indicates decreases in cost per covered person. The early study25 of 
benefits expansion from the first executive order reported an increase in cost but this 
occurred prior to managed care and during a period when adverse selection was a serious 
problem faced by the major FEHB plans.35 National estimates of weighted single and family 
premiums for fee for service (FFS) plans for the year 2000 was an average of $2382, the 
approximate mid-point of the FEHB evaluations (Table 1). Premiums for PPOs were not 
readily available from OPM. One study23,34 that assessed the impact on all adult enrollees 
and both MH and SA claims found that plan cost per person per year for MH/SA decreased 
in six plans (minimum of 0.06% and maximum of 1.03%) and increased in 1 plan by 0.21%, 
where the percentage changes are calculated with respect to weighted single and family 
2000 premiums. Another study20 based on claims for MH/SA for child beneficiaries found 
that MH/SA cost per child (inclusive of OOP cost) increased by 0.17% in one plan and 
decreased in six plans, with minimum and maximum decreases of 0.14% and 0.79% 
respectively with reference to year 2000 premiums for family coverage weighted for number 
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of dependents. The study showed that OOP cost per child user decreased across all 7 plans 
but it was not possible to obtain change in plan cost per child enrollee from the information 
provided. The third study21 found that SA plan cost per adult enrollee decreased by 0.013% 
in terms of year 2000 weighted single and family premiums.
State mandates—The federal Mental Health Parity Act of 1996 (MHPA) had limited 
scope, in part, because parity applied only to annual and lifetime dollar limits and did not 
cover SA and its treatment. Several state legislatures enacted their own stronger parity laws 
immediately after passage of the MHPA and thereafter, only a few of which were evaluated. 
Included in the economic evidence are two studies that assessed the effect of parity 
mandates on plan costs for the State of Oregon27 and the State of Vermont28 (Table 2). The 
Oregon study27 found that the increase in plan cost per person ranged from 0.23% to 0.63% 
of weighted single and family premiums for mixed provider coverages. The Vermont 
study28 found that plan cost per person increased by 0.1% in terms of percent of weighted 
single and family premiums for mixed provider coverage.
Individual employers—Five studies22,24,29–33 assessed the impact on cost for individual 
large employers that expanded their MH/SA benefits voluntarily or in response to 
administrative rule (Table 3). In the case of one study,22 this review assumed the cost 
estimate excluded OOP cost though it was not clearly stated to be so in the study. Details 
whether plan-holders and dependents are included in the observed claims data and the 
choice of estimate for premiums used to compute the percentage change in plan cost are 
available within the table. Of these studies, two22,24 found that plan cost PPPY decreased 
(6.74% and 0.28% of premiums) and one29 found that it increased by 1.07%. Of the 
remaining two studies, one30 reported mixed results (0.29% in the HMO and −0.76% in 
indemnity plans) and the other31–33 found no change in plan cost for the employer.
Cost per averted suicide
The one study26 that reported final morbidity and mortality outcomes estimated the cost per 
averted suicides ascribable to state parity mandates for MH/SA benefits, where cost was 
drawn from increase in premiums estimated in the literature. The study estimated that these 
mandates averted 592 suicides per year nationwide, at a cost of $1.3–$3.1 million per 
suicide averted.
Summary of Results—There were no studies of MH/SA benefits expansion that reported 
cost per QALY saved or cost-benefit outcomes. Hence, there was insufficient information to 
determine whether the interventions were cost-effective or cost-beneficial.
Ten of the eleven studies that evaluated cost impact on health plans were based on data from 
1996 onwards, three of which showed decreases in plan cost PPPY while two showed 
decreases in 6 of the 7 plans they considered. There was no change in cost PPPY for one 
study while it was mixed (0.29% and −0.76%) in another. Of the three remaining studies, 
two showed an increase in cost PPPY to be 0.63% or less, and the other an increase of 
1.07%, respectively. The evidence from economic evaluation studies indicates that MH/SA 
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benefits expansion did not lead to any substantial increase in cost to health insurance plans, 
measured as a percentage of premiums.
Discussion
During the period covered in this review, arguments were made for and against parity for 
MH/SA benefits in the US and the latter included the possibility that plans would face 
formidable increases in cost. Modeling exercises were conducted in the 1990s, under the 
aegis of the Congressional Budget office (CBO) and the National Advisory Mental Health 
Council (NAMHC), to predict the expected cost increases following the expansion of 
MH/SA benefits towards parity. The history of their predictions is traced36 from the initial 
estimated increase in premiums of 4.0% predicted to follow the Mental Health Parity Act 
(MHPA) of 1996 to the lower 3.6% increase predicted from actuarial-economic models and 
observed experience in 1998. Further evidence from the FEHB experience and several large 
behavioral carve-outs were then used to calibrate the actuarial-economic model and the 
impact was further revised downward to a 1.4% increase in premiums.36 The models 
predicted smaller increases in premiums as a result of incorporating the effects of managed 
care activities on treatments and the smaller estimates of MH/SA demand elasticity in 
managed care settings.
With all but one estimated increase below 1% and many plans showing actual decreases in 
cost PPPY, the evidence from this systematic review indicates that costs are likely to 
increase far less than the predictions made during and around the time of the MHPA federal 
law of 1996. In fact, the findings of this review are consistent with the CBO prediction that 
the MHPAEA of 2008 would result in a 0.4% increase in premiums.37,38 A recent historical 
review of the processes that led to the MHPAEA of 2008 ascribed the success of its passage 
partly to data showing there was little to no effect on plan costs due to earlier parity or other 
benefit expansion.39 The present study echoes the observation with evidence based on a 
systematic review.
The much smaller increase in cost, if any, observed in the parity studies compared to the 
predictions from earlier actuarial models merits additional comment. A key difference is that 
the early actuarial models were based on experience and data that were not moderated by 
managed care practices while these practices were very much in play within the plans 
analyzed in the parity studies included in this review. Further, effective pharmacotherapy 
and its increased use in treatment of MH/SA likely also confounded the pathway from 
benefits expansion to cost of utilization. In the case of the FEHB, OPM actually encouraged 
the use of managed care to control cost and all but one of the plans included in the FEHB 
studies were carved-out to managed behavioral health organizations (MBHOs). As shown in 
column 3 of tables 2 and 3, carve-outs were also the dominant organization that managed 
MH/SA in the State and large employer parity studies.
The study26 on state suicide rates is the only study in this body of evidence to provide a cost 
per unit of health outcome ascribable to MH/SA benefits expansion. Future economic 
research needs to allow more adequately for concurrent effects of general and medical care 
inflation on cost, innovations in pharmaceuticals, changes in prescription patterns, and 
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secular trends in the diagnosis and treatment of mental illnesses and SA. Very few studies 
evaluated the more downstream effects on business decisions about labor, such as effects on 
hiring, retention, and the offer of health benefits as part of a compensation package. This 
gap is noted considering that about 60% of the U.S. non-elderly insured have employer-
sponsored insurance and laws apply differently across employers of different sizes, as was 
the case for the federal laws and state mandates included in both the effectiveness review13 
and this economic review. One other limitation of the review is that the included studies 
only considered claims coded for mental health and do not account for physical health 
claims that may have had an underlying mental health condition. Such patients may have 
more readily sought appropriate mental health care with the advent of parity.
U.S. Implications for MH/SA Care Provision and Use
Policies on MH/SA benefits in health insurance evolved through a long history of laws and 
rules at the US federal level, numerous mandates at the state level, and voluntary expansions 
by large self-insured employers. MH/SA benefits legislation at the federal level culminated 
in the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA),38 as amended by 
the Health Care and Education Reconciliation Act of 2010 (commonly jointly referred to as 
the Affordable Care Act, or ACA). MHPAEA38 extended parity requirements to mental 
health and substance use disorder benefits provided by plans in the large group health 
insurance market, applicable to financial requirements such as co-pays and deductibles, and 
to treatment limitations such as limits on outpatient and inpatient visits.40 The ACA added 
mental health and substance use disorder protections in addition to those enacted under 
MHPAEA by requiring that certain plans offer minimum mental health/substance use 
disorder benefits, including behavioral health treatment, as one of the essential health benefit 
categories,41 generally expanding the population with health care coverage,42 and 
eliminating pre-existing condition clauses from most plans.43 The ACA also enhanced 
Medicaid coverage options for serious and persistent mental illness and applied MHPAEA 
and essential health benefit requirements to Medicaid alternative benefit plans.44 The likely 
effect of these changes on the mental health and substance abuse costs of different health 
insurance plans is the subject of future research.45
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Flow chart of article selection
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